Sign in
Taking people in United StatesNo phase

Collecting blood from pregnant women to develop a prenatal test for Down syndrome

Collects blood from pregnant women to help develop a prenatal test for Down syndrome.

Key facts

Who runs it
Sequenom, Inc.
Where
Birmingham, Camden, Charleston, Chicago, Detroit, Grand Rapids, Iowa City, Los Angeles, and San Diego, United StatesSee the 12 sitesAlso in 1 other country, 2 sites
Trial code
Registry title
Specimen Collection From Pregnant Women at Increased Risk for Fetal Aneuploidy
Status
Recruiting
People taking part
2,000 people, planned
Started
May 2011
Expected to end
Mar 2028
Type of study
Observational
Record updated
9 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for pregnant women whose baby has a higher chance of a chromosome problem. They give blood samples to help build a blood test for T21 (Down syndrome) during pregnancy.

Age
18 years or older
Sex
Women only
Disease stage
Pregnant between 10 and 22 weeks, with a higher chance that the baby has a chromosome abnormality (fetal aneuploidy).

Main reasons for not taking part

  • The baby has died at the time the sample is taken
  • Already gave a sample in this trial
  • Not willing to have a CVS and/or amniocentesis (tests that take a sample from the womb) for genetic testing
  • Not willing to share the genetic results of that test

This trial only enrols pregnant participants. The registry sentence this rests on: * pregnant between 10 and 22 weeks gestation

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • pregnant between 10 and 22 weeks gestation
  • 18 years of age or older
  • provides signed and dated informed consent
  • subject is at increased risk for fetal aneuploidy
  • subject is willing to undergo a CVS and/or amniocentesis procedure for the purpose of genetic analysis
  • subject agrees to provide the genetic results of the invasive procedure

Who cannot take part

  • Previous sample donation under this protocol
  • Fetal demise at time of specimen sampling

Where in United States

Also in 1 other country, 2 sites

  • University of Alabama BirminghamBirmingham, United StatesContact: Rachel CopperTaking people
  • The Cooper Health SystemCamden, United StatesContact: Clare HansonTaking people
  • Medical University of South CarolinaCharleston, United StatesContact: Betty OswaldTaking people
  • Reproductive Genetics InstituteChicago, United StatesContact: Denise GinsbergTaking people
  • Henry Ford HospitalDetroit, United StatesContact: Ellen MartindellTaking people
  • Spectrum HealthGrand Rapids, United StatesContact: Yvonne EdgerlyTaking people
  • University of Iowa Health CareIowa City, United StatesContact: Diedre FleenerTaking people
  • Cedars-Sinai Medical CenterLos Angeles, United StatesContact: Deebra Smith, MDTaking people
  • Sharp-Rees Stealy Medical GroupSan Diego, United StatesContact: Mary LaPageTaking people
  • Specialty Obstetrics of San DiegoSan Diego, United StatesContact: Deborah MaloneTaking people
  • UCSDSan Diego, United StatesContact: Jason ChibuckTaking people
  • Women's Health Care ResearchSan Diego, United StatesContact: Nora MartinezTaking people

About the trial

What the trial wants to find out

The specimen collection is designed for the purpose of the development of a noninvasive prenatal test for T21.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Collection of Whole Blood Specimens From Pregnant Women at Increased Risk of Fetal Chromosomal Abnormality for Use in Development of a Noninvasive Prenatal Test in the Detection of the Relative Quantity of Chromosomal Material in Circulating Cell-Free DNA Extracted From Maternal Plasma
Plain-language title
Collecting blood from pregnant women to develop a prenatal test for Down syndromeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
9 September 2026